Cargando…
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?
BACKGROUND: More than 6,800 rare diseases and conditions have been identified in the US, which affect 25–30 million Americans. In 1983, the US Congress enacted the Orphan Drug Act (ODA) to encourage the development and marketing of drugs to treat rare diseases and conditions. This study analyzed all...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217554/ https://www.ncbi.nlm.nih.gov/pubmed/28057032 http://dx.doi.org/10.1186/s13023-016-0551-7 |